Development of ultrasound-responsive liposomes for the evasion of doxorubicin-induced systemic immunosuppression
발표자
()
초록
내용
Doxorubicin (DOX) is a widely used anticancer agent, which is capable of boosting the immune system via immunogenic cell death (ICD). However, clinical usage still remains limited due to its dose-dependent toxicity and systemic side effects. In this study, we designed DOX-containing ultrasound-responsive liposomes (IMP301) which can elicit site-specific anticancer activities in the presence of ultrasound. IMP301 enhanced the maturation of antigen-presenting cells (APC) and tumor infiltration of cytotoxic T lymphocytes, while reducing hemosiderosis compared with DOX treatment. Moreover, IMP301 significantly inhibited tumor growth in response to ultrasound irradiation, delaying tumor doubling time to more than 20 days compared with control group. Furthermore, combination therapy with immune checkpoint inhibitors showed synergetic effects in tumor regression, eliminating 75% of established tumors. Consequently, IMP301 may be a potential therapeutic agent for cancer immunotherapy.